2023

Research team from IDIBELL and UB find that HERC1 protein deficiency causes osteopenia

Scientists from IDIBELL and the University of Barcelona identify how HERC1 deficiency unbalances bone homeostasis, causing osteopenia. These results identify potential therapeutic targets for individuals with bone diseases and HERC1 deficiency.

Research team from IDIBELL and UB find that HERC1 protein deficiency causes osteopenia Read More »

New evidence for the correct detection of oropharyngeal cancers caused by the human papillomavirus

To establish whether oropharyngeal cancer was related to the human papillomavirus, the recomendation is do it through the p16 protein detection.
Now a study from IDIBELL published in The Lancet Oncology has shown that not all p16-positive oropharyngeal cancers are caused by the virus.

New evidence for the correct detection of oropharyngeal cancers caused by the human papillomavirus Read More »

An investigation by HUB and IDIBELL shows the adaptation of bacteria in COPD patients and prolonged treatment with azithromycin

The IDIBELL Bacterial Epidemiology research group has published a paper on the adaptation of Haemophilus spp in patients with chronic obstructive pulmonary disease (COPD) and prolonged treatment with azithromycin.

An investigation by HUB and IDIBELL shows the adaptation of bacteria in COPD patients and prolonged treatment with azithromycin Read More »

Association between polyphenols from diet and body weight change

The results, published in Antioxidant and Obesity scientific journals, show that the intake of most polyphenols is associated with maintenance or a lower weight gain, highlighting those polyphenols present in fruits, vegetables, olive oil, tea, cocoa, or cereals integral.

Association between polyphenols from diet and body weight change Read More »

A drug that prevents DNA reparation could improve the survival of patients with one of the most aggressive prostate cancers

The results of the TRITON3 study show that patients with prostate cancer treated with a PARP inhibitor, called Rucaparib, take almost twice as long for the disease to progress than those treated with conventional chemotherapy.

A drug that prevents DNA reparation could improve the survival of patients with one of the most aggressive prostate cancers Read More »

The Govern awards the Josep Trueta plaque for health merit to the Hospital de Bellvitge

The Govern approved today the awarding of the Josep Trueta medals and plaques to outstanding professionals and entities in the health field. Among the award-winning entities is the Bellvitge University Hospital, for its work as a reference center of maximum complexity for 2 million people. Likewise, one of the individual medals has been for Dr. Mònica Povedano, a neurologist at Hospital de Bellvitge and IDIBELL researcher.

The Govern awards the Josep Trueta plaque for health merit to the Hospital de Bellvitge Read More »

An anti-diabetic and anti-inflammatory diet before the disease may contribute to a better prognosis in breast cancer survivors

A study led by researchers from the Nutrition and Cancer research group of the Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan Institute of Oncology (ICO) examined the relationship between dietary patterns before breast cancer diagnosis and the survival of these patients.

An anti-diabetic and anti-inflammatory diet before the disease may contribute to a better prognosis in breast cancer survivors Read More »

Great success of the 6th sLHam of women scientists

With the Barradas auditorium full, the 6th IDIBELL sLHam of female scientists was a total success. This year the sLHameres were Sandra Acosta, Begoña Arán, Lidia Franco, Núria Lloberas, Patricia Prada and Gemma Via, Fatima Akhtar and Paula Barrios, who, in a five-minute informative talk, explained their career in the scientific world, the challenges they have been overcoming and the motivations that have helped them to do so.

Great success of the 6th sLHam of women scientists Read More »

Scroll to Top